Skip to main content
Top
Published in: Endocrine 3/2016

01-06-2016 | Original Article

Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation

Authors: Silvia Morelli, Gianpaolo Reboldi, Sonia Moretti, Elisa Menicali, Nicola Avenia, Efisio Puxeddu

Published in: Endocrine | Issue 3/2016

Login to get access

Abstract

Oral levothyroxine (L-T4) is the mainstay of hypothyroidism treatment. Many factors may influence its absorption, including the timing of administration. Objective of the study is to demonstrate the therapeutic equivalence of administering liquid L-T4 with breakfast or 10 min before breakfast. This was a pilot study conducted with a crossover design AB/BA where A stays for L-T4 with breakfast and B for L-T4 10 min before breakfast. A post hoc analysis was conducted to compare L-T4 administered at breakfast or 10 min before breakfast with L-T4 administered 30 min before breakfast. Sixty-one hypothyroid patients were enrolled and assigned to one of the two treatment sequences. All patients were evaluated for TSH levels at the end of each period. Fifty-nine patients completed the study. The mean thyrotropin concentration was 1.52 ± 0.73 µU/ml when L-T4 was administered with breakfast and 1.46 ± 0.81 µU/ml when it was taken 10 min before breakfast, without clinically and statistically significant differences (P = 0.59), regardless of treatment sequence and period. The mean thyrotropin concentration was 1.54 ± 0.9 µU/ml when L-T4 was administered at 0–10 min intervals before breakfast and 1.25 ± 0.7 µU/ml when it was taken 30 min before breakfast (ratio = 1.23, within our definition of equivalence set at 0.8–1.25). There is therapeutic equivalence between liquid L-T4 administration at breakfast or 10 min before breakfast. We can also hypothesize that there are no clinically relevant differences between liquid L-T4 administration 30 min before breakfast or at shorter intervals.
Literature
1.
go back to reference M. Centanni, A. Franchi, M.G. Santaguida, C. Virili, S. Nardo, L. Gargano, Oral thyroxine treatment: towards an individually tailored dose. Recenti Prog. Med. 98, 445–451 (2007)PubMed M. Centanni, A. Franchi, M.G. Santaguida, C. Virili, S. Nardo, L. Gargano, Oral thyroxine treatment: towards an individually tailored dose. Recenti Prog. Med. 98, 445–451 (2007)PubMed
2.
go back to reference R. Vita, P. Fallahi, A. Antonelli, S. Benvenga, The administration of L-thyroxine as soft gel capsule or liquid solution. Expert Opin. Drug Deliv. 11, 1103–1111 (2014)CrossRefPubMed R. Vita, P. Fallahi, A. Antonelli, S. Benvenga, The administration of L-thyroxine as soft gel capsule or liquid solution. Expert Opin. Drug Deliv. 11, 1103–1111 (2014)CrossRefPubMed
3.
go back to reference L.H. Fish, H.L. Schwartz, J. Cavanaugh, M.W. Steffes, J.P. Bantle, J.H. Oppenheimer, Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N. Engl. J. Med. 316, 764–770 (1987)CrossRefPubMed L.H. Fish, H.L. Schwartz, J. Cavanaugh, M.W. Steffes, J.P. Bantle, J.H. Oppenheimer, Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N. Engl. J. Med. 316, 764–770 (1987)CrossRefPubMed
4.
5.
go back to reference K.W. Wenzel, H.E. Kirschsieper, Aspects of the absorption of oral L-thyroxine in normal man. Metabolism. 26, 1–8 (1977)CrossRefPubMed K.W. Wenzel, H.E. Kirschsieper, Aspects of the absorption of oral L-thyroxine in normal man. Metabolism. 26, 1–8 (1977)CrossRefPubMed
7.
go back to reference M. Centanni, Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches. Endocrine 43, 8–9 (2013)CrossRefPubMed M. Centanni, Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches. Endocrine 43, 8–9 (2013)CrossRefPubMed
8.
go back to reference L. Liwanpo, J.M. Hershman, Conditions and drugs interfering with thyroxine absorption. Best Pract. Res. Clin. Endocrinol. Metab. 23, 781–792 (2009)CrossRefPubMed L. Liwanpo, J.M. Hershman, Conditions and drugs interfering with thyroxine absorption. Best Pract. Res. Clin. Endocrinol. Metab. 23, 781–792 (2009)CrossRefPubMed
9.
10.
go back to reference F. Santini, A. Pinchera, A. Marsili, G. Ceccarini, M.G. Castagna, R. Valeriano, M. Giannetti, D. Taddei, R. Centoni, G. Scartabelli, T. Rago, C. Mammoli, R. Elisei, P. Vitti, Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J. Clin. Endocrinol. Metab. 90, 124–127 (2005)CrossRefPubMed F. Santini, A. Pinchera, A. Marsili, G. Ceccarini, M.G. Castagna, R. Valeriano, M. Giannetti, D. Taddei, R. Centoni, G. Scartabelli, T. Rago, C. Mammoli, R. Elisei, P. Vitti, Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J. Clin. Endocrinol. Metab. 90, 124–127 (2005)CrossRefPubMed
11.
go back to reference J. Jonklaas, Sex and age differences in levothyroxine dosage requirement. Endocr. Pract. 16, 71–79 (2010)CrossRefPubMed J. Jonklaas, Sex and age differences in levothyroxine dosage requirement. Endocr. Pract. 16, 71–79 (2010)CrossRefPubMed
12.
go back to reference R.L. Rosenbaum, U.S. Barzel, Levothyroxine replacement dose for primary hypothyroidism decreases with age. Ann. Intern. Med. 96, 53–55 (1982)CrossRefPubMed R.L. Rosenbaum, U.S. Barzel, Levothyroxine replacement dose for primary hypothyroidism decreases with age. Ann. Intern. Med. 96, 53–55 (1982)CrossRefPubMed
13.
go back to reference C.T. Sawin, T. Herman, M.E. Molitch, M.H. London, S.M. Kramer, Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. Am. J. Med. 75, 206–209 (1983)CrossRefPubMed C.T. Sawin, T. Herman, M.E. Molitch, M.H. London, S.M. Kramer, Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. Am. J. Med. 75, 206–209 (1983)CrossRefPubMed
14.
go back to reference M. Devdhar, R. Drooger, M. Pehlivanova, G. Singh, J. Jonklaas, Levothyroxine replacement doses are affected by gender and weight, but not age. Thyroid. 21, 821–827 (2011)CrossRefPubMedPubMedCentral M. Devdhar, R. Drooger, M. Pehlivanova, G. Singh, J. Jonklaas, Levothyroxine replacement doses are affected by gender and weight, but not age. Thyroid. 21, 821–827 (2011)CrossRefPubMedPubMedCentral
15.
go back to reference J.A. Loh, L. Wartofsky, J. Jonklaas, K.D. Burman, The magnitude of increased levothyroxine requirements in hypothyroid pregnant women depends upon the etiology of the hypothyroidism. Thyroid. 19, 269–275 (2009)CrossRefPubMed J.A. Loh, L. Wartofsky, J. Jonklaas, K.D. Burman, The magnitude of increased levothyroxine requirements in hypothyroid pregnant women depends upon the etiology of the hypothyroidism. Thyroid. 19, 269–275 (2009)CrossRefPubMed
16.
go back to reference D.J. Lips, M.T. van Reisen, V. Voigt, W. Venekamp, Diagnosis and treatment of levothyroxine pseudomalabsorption. Neth. J. Med. 62, 114–118 (2004)PubMed D.J. Lips, M.T. van Reisen, V. Voigt, W. Venekamp, Diagnosis and treatment of levothyroxine pseudomalabsorption. Neth. J. Med. 62, 114–118 (2004)PubMed
17.
go back to reference M.B. Gordon, M.S. Gordon, Variations in adequate levothyroxine replacement therapy in patients with different causes of hypothyroidism. Endocr. Pract. 5, 233–238 (2004)CrossRef M.B. Gordon, M.S. Gordon, Variations in adequate levothyroxine replacement therapy in patients with different causes of hypothyroidism. Endocr. Pract. 5, 233–238 (2004)CrossRef
18.
go back to reference L.A. Burmeister, M.O. Goumaz, C.N. Mariash, J.H. Oppenheimer, Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 75, 344–350 (1992)PubMed L.A. Burmeister, M.O. Goumaz, C.N. Mariash, J.H. Oppenheimer, Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 75, 344–350 (1992)PubMed
19.
go back to reference M. Torlontano, C. Durante, I. Torrente, U. Crocetti, G. Augello, G. Ronga, T. Montesano, L. Travascio, A. Verrienti, R. Bruno, S. Santini, P. D’Arcangelo, B. Dallapiccola, S. Filetti, V. Trischitta, Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J. Clin. Endocrinol. Metab. 93, 910–913 (2008)CrossRefPubMed M. Torlontano, C. Durante, I. Torrente, U. Crocetti, G. Augello, G. Ronga, T. Montesano, L. Travascio, A. Verrienti, R. Bruno, S. Santini, P. D’Arcangelo, B. Dallapiccola, S. Filetti, V. Trischitta, Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J. Clin. Endocrinol. Metab. 93, 910–913 (2008)CrossRefPubMed
20.
go back to reference K.A. Heemstra, H.C. Hoftijzer, W.M. van der Deure, R.P. Peeters, E. Fliers, B.C. Appelhof, W.M. Wiersinga, E.P. Corssmit, T.J. Visser, J.W. Smit, Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis. Clin. Endocrinol. 71, 279–283 (2009)CrossRef K.A. Heemstra, H.C. Hoftijzer, W.M. van der Deure, R.P. Peeters, E. Fliers, B.C. Appelhof, W.M. Wiersinga, E.P. Corssmit, T.J. Visser, J.W. Smit, Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis. Clin. Endocrinol. 71, 279–283 (2009)CrossRef
21.
go back to reference E. Lahner, C. Virili, M.G. Santaguida, B. Annibale, M. Centanni, Helicobacter pylori infection and drugs malabsorption. World J. Gastroenterol. 20, 10331–10337 (2014)CrossRefPubMedPubMedCentral E. Lahner, C. Virili, M.G. Santaguida, B. Annibale, M. Centanni, Helicobacter pylori infection and drugs malabsorption. World J. Gastroenterol. 20, 10331–10337 (2014)CrossRefPubMedPubMedCentral
22.
go back to reference M. Centanni, L. Gargano, G. Canettieri, N. Viceconti, A. Franchi, G. Delle Fave, B. Annibale, Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N. Engl. J. Med. 354, 1787–1795 (2006)CrossRefPubMed M. Centanni, L. Gargano, G. Canettieri, N. Viceconti, A. Franchi, G. Delle Fave, B. Annibale, Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N. Engl. J. Med. 354, 1787–1795 (2006)CrossRefPubMed
23.
go back to reference S. Checchi, A. Montanaro, L. Pasqui, C. Ciuoli, V. De Palo, M.C. Chiappetta, F. Pacini, L-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. J. Clin. Endocrinol. Metab. 93, 465–469 (2008)CrossRefPubMed S. Checchi, A. Montanaro, L. Pasqui, C. Ciuoli, V. De Palo, M.C. Chiappetta, F. Pacini, L-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. J. Clin. Endocrinol. Metab. 93, 465–469 (2008)CrossRefPubMed
24.
go back to reference C. Virili, G. Bassotti, M.G. Santaguida, R. Iuorio, S.C. Del Duca, V. Mercuri, A. Picarelli, P. Gargiulo, L. Gargano, M. Centanni, Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J. Clin. Endocrinol. Metab. 97, 419–422 (2012)CrossRef C. Virili, G. Bassotti, M.G. Santaguida, R. Iuorio, S.C. Del Duca, V. Mercuri, A. Picarelli, P. Gargiulo, L. Gargano, M. Centanni, Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J. Clin. Endocrinol. Metab. 97, 419–422 (2012)CrossRef
25.
go back to reference M. Cellini, M.G. Santaguida, I. Gatto, C. Virili, S.C. Del Duca, N. Brusca, S. Capriello, L. Gargano, M. Centanni, Systematic appraisal of lactose intolerance as cause of increased need for oral thyroxine. J. Clin. Endocrinol. Metab. 99, 1454–1458 (2014)CrossRef M. Cellini, M.G. Santaguida, I. Gatto, C. Virili, S.C. Del Duca, N. Brusca, S. Capriello, L. Gargano, M. Centanni, Systematic appraisal of lactose intolerance as cause of increased need for oral thyroxine. J. Clin. Endocrinol. Metab. 99, 1454–1458 (2014)CrossRef
26.
go back to reference T.G. Bach-Huynh, B. Nayak, J. Loh, S. Soldin, J. Jonklaas, Timing of levothyroxine administration affects serum thyrotropin concentration. J. Clin. Endocrinol. Metab. 94, 3905–3912 (2009)CrossRefPubMedPubMedCentral T.G. Bach-Huynh, B. Nayak, J. Loh, S. Soldin, J. Jonklaas, Timing of levothyroxine administration affects serum thyrotropin concentration. J. Clin. Endocrinol. Metab. 94, 3905–3912 (2009)CrossRefPubMedPubMedCentral
27.
go back to reference R. Rajput, S. Chatterjee, M. Rajput, Can levothyroxine be taken as evening dose? Comparative evaluation of morning versus evening dose of levothyroxine in treatment of hypothyroidism. J. Thyroid Res. 505239 (2011). doi:10.4061/2011/505239 PubMedPubMedCentral R. Rajput, S. Chatterjee, M. Rajput, Can levothyroxine be taken as evening dose? Comparative evaluation of morning versus evening dose of levothyroxine in treatment of hypothyroidism. J. Thyroid Res. 505239 (2011). doi:10.​4061/​2011/​505239 PubMedPubMedCentral
28.
go back to reference C. Cappelli, I. Pirola, E. Gandossi, A. Formenti, M. Castellano, Oral liquid levothyroxine treatment at breakfast: a mistake? Eur. J. Endocrinol. 170, 95–99 (2013)CrossRefPubMed C. Cappelli, I. Pirola, E. Gandossi, A. Formenti, M. Castellano, Oral liquid levothyroxine treatment at breakfast: a mistake? Eur. J. Endocrinol. 170, 95–99 (2013)CrossRefPubMed
29.
go back to reference J. Ware Jr, M. Kosinski, S.D. Keller, A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med. Care 34, 220–233 (1996)CrossRefPubMed J. Ware Jr, M. Kosinski, S.D. Keller, A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med. Care 34, 220–233 (1996)CrossRefPubMed
30.
go back to reference S.S. Senn, Cross-over Trials in Clinical Research (John Wiley, Chichester, 2002)CrossRef S.S. Senn, Cross-over Trials in Clinical Research (John Wiley, Chichester, 2002)CrossRef
31.
go back to reference M.P. Vanderpump, W.M. Tunbridge, J.M. French, D. Appleton, D. Bates, F. Clark, J. Grimley Evans, D.M. Hasan, H. Rodgers, F. Tunbridge, E.T. Young, The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. 43, 55–68 (1995)CrossRef M.P. Vanderpump, W.M. Tunbridge, J.M. French, D. Appleton, D. Bates, F. Clark, J. Grimley Evans, D.M. Hasan, H. Rodgers, F. Tunbridge, E.T. Young, The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. 43, 55–68 (1995)CrossRef
32.
go back to reference C.T. Sawin, W.P. Castelli, J.M. Hershman, P. McNamara, P. Bacharach, The aging thyroid. Thyroid deficiency in the Framingham Study. Arch. Intern. Med. 145, 1386–1388 (1985)CrossRefPubMed C.T. Sawin, W.P. Castelli, J.M. Hershman, P. McNamara, P. Bacharach, The aging thyroid. Thyroid deficiency in the Framingham Study. Arch. Intern. Med. 145, 1386–1388 (1985)CrossRefPubMed
33.
go back to reference J.G. Hollowell, N.W. Staehling, W.D. Flanders, W.H. Hannon, E.W. Gunter, C.A. Spencer, L.E. Braverman, Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 87, 489–499 (2002)CrossRefPubMed J.G. Hollowell, N.W. Staehling, W.D. Flanders, W.H. Hannon, E.W. Gunter, C.A. Spencer, L.E. Braverman, Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 87, 489–499 (2002)CrossRefPubMed
34.
go back to reference G.J. Canaris, N.R. Manowitz, G. Mayor, E.C. Ridgway, The Colorado thyroid disease prevalence study. Arch. Intern. Med. 160, 526–534 (2000)CrossRefPubMed G.J. Canaris, N.R. Manowitz, G. Mayor, E.C. Ridgway, The Colorado thyroid disease prevalence study. Arch. Intern. Med. 160, 526–534 (2000)CrossRefPubMed
35.
go back to reference J.R. Garber, R.H. Cobin, H. Gharib, J.V. Hennessey, I. Klein, J.I. Mechanick, R. Pessah-Pollack, P.A. Singer, K.A. Woeber, American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults, Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr. Pract. 18, 988–1028 (2012)CrossRefPubMed J.R. Garber, R.H. Cobin, H. Gharib, J.V. Hennessey, I. Klein, J.I. Mechanick, R. Pessah-Pollack, P.A. Singer, K.A. Woeber, American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults, Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr. Pract. 18, 988–1028 (2012)CrossRefPubMed
36.
go back to reference M.I. Surks, E. Ortiz, G.H. Daniels, C.T. Sawin, N.F. Col, R.H. Cobin, J.A. Franklyn, J.M. Hershman, K.D. Burman, M.A. Denke, C. Gorman, R.S. Cooper, N.J. Weissman, Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management. JAMA 291, 228–238 (2004)CrossRefPubMed M.I. Surks, E. Ortiz, G.H. Daniels, C.T. Sawin, N.F. Col, R.H. Cobin, J.A. Franklyn, J.M. Hershman, K.D. Burman, M.A. Denke, C. Gorman, R.S. Cooper, N.J. Weissman, Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management. JAMA 291, 228–238 (2004)CrossRefPubMed
38.
go back to reference R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J. Clin. Endocrinol. Metab. 99, 4481–4486 (2014)CrossRefPubMed R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J. Clin. Endocrinol. Metab. 99, 4481–4486 (2014)CrossRefPubMed
39.
go back to reference I. Walter-Sack, C. Clanget, R. Ding, C. Goeggelmann, V. Hinke, M. Lang, J. Pfeilschifter, Y. Tayrouz, K. Weqscheider, Assessment of levothyroxine sodium bioavailability: recommendations for an improved methodology based on the pooled analysis of eight identically designed trials with 396 drug exposures. Clin. Pharmacokinet. 43, 1037–1053 (2004)CrossRefPubMed I. Walter-Sack, C. Clanget, R. Ding, C. Goeggelmann, V. Hinke, M. Lang, J. Pfeilschifter, Y. Tayrouz, K. Weqscheider, Assessment of levothyroxine sodium bioavailability: recommendations for an improved methodology based on the pooled analysis of eight identically designed trials with 396 drug exposures. Clin. Pharmacokinet. 43, 1037–1053 (2004)CrossRefPubMed
40.
go back to reference M.G. Santaguida, C. Virili, S.C. Del Duca, M. Cellini, I. Gatto, N. Brusca, C. De Vito, L. Gargano, M. Centanni, Thyroxine softgel capsule in patients with gastric-related T4 malabsorption. Endocrine 49, 51–57 (2015)CrossRefPubMed M.G. Santaguida, C. Virili, S.C. Del Duca, M. Cellini, I. Gatto, N. Brusca, C. De Vito, L. Gargano, M. Centanni, Thyroxine softgel capsule in patients with gastric-related T4 malabsorption. Endocrine 49, 51–57 (2015)CrossRefPubMed
41.
go back to reference R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 43, 154–160 (2013)CrossRefPubMed R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 43, 154–160 (2013)CrossRefPubMed
Metadata
Title
Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation
Authors
Silvia Morelli
Gianpaolo Reboldi
Sonia Moretti
Elisa Menicali
Nicola Avenia
Efisio Puxeddu
Publication date
01-06-2016
Publisher
Springer US
Published in
Endocrine / Issue 3/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0788-2

Other articles of this Issue 3/2016

Endocrine 3/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine